RU2015110071A - APPLICATION OF NEW CHEMICAL COMPOUNDS (OPTIONS) AS NUAK1 KINASE INHIBITORS FOR TREATMENT OF ONCOLOGICAL DISEASES - Google Patents
APPLICATION OF NEW CHEMICAL COMPOUNDS (OPTIONS) AS NUAK1 KINASE INHIBITORS FOR TREATMENT OF ONCOLOGICAL DISEASES Download PDFInfo
- Publication number
- RU2015110071A RU2015110071A RU2015110071A RU2015110071A RU2015110071A RU 2015110071 A RU2015110071 A RU 2015110071A RU 2015110071 A RU2015110071 A RU 2015110071A RU 2015110071 A RU2015110071 A RU 2015110071A RU 2015110071 A RU2015110071 A RU 2015110071A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- tetrahydropyrazino
- carboxamide
- dichlorobenzyl
- independently selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Применение соединения формулы I:или его энантиомера или фармацевтически приемлемой соли, сольвата или гидрата,где Lпредставляет собой СНили СН(СН);Lпредставляет собой C(O)NH или NH;цикл А представляет собой фенил, опционально замещенный 1-3 группами R;Rвыбирается независимо и представляет собой галоген, частично или полностью галогенированный С-алкил, ОС-алкил;цикл В представляет собой фенил или 6-членный гетероарильный цикл, содержащий 1-2 атома N; цикл В необязательно содержит 1-3 заместителя R;Rвыбирается независимо и представляет собой L-R, L-H, галоген, частично или полностью галогенированный C-алкил;Lпредставляет собой ковалентную химическую связь, О, ОСНили С(О);Rвыбирается независимо и представляет собой С-алкил, 4-6 членный гетероалициклил, содержащий 1-2 атома N и 0-1 атом О; Rнеобязательно содержит 1-3 заместителя R;Rвыбирается независимо и представляет собой галоген, СН, NHR, N(R)или 5-6 членный гетероалициклил, содержащий 0-1 атом N и 0-1 атом О; Rнеобязательно содержит 1-2 заместителя, которые независимо выбираются из С-алкилов;Rвыбирается независимо и представляет собой С-алкил;для получения фармацевтической композиции для лечения и/или предотвращения заболевания, связанного с аберрантной активностью NUAK1 киназы.2. Применение по п. 1, в котором:Lпредставляет собой СН;Lпредставляет собой C(O)NH;цикл А представляет собой фенил, опционально замещенный 1-3 группами R;Rвыбирается независимо и представляет собой галоген или CF;цикл В представляет собой фенил; цикл В необязательно содержит 1-3 заместителя R;Rвыбирается независимо и представляет собой L-R, L-H;Lпредставляет собой ковалентную химическую связь, О, ОСНили С(О);Rвыбирается независимо и представляет собой 4-6 членный гетероалициклил, содержащий 1-2 атома N и 0-11. The use of a compound of formula I: or an enantiomer thereof or a pharmaceutically acceptable salt, solvate or hydrate, where L is CH or CH (CH); L is C (O) NH or NH; cycle A is phenyl optionally substituted with 1-3 groups R; R is independently selected and is halogen, partially or fully halogenated C-alkyl, OC-alkyl; cycle B is a phenyl or 6-membered heteroaryl ring containing 1-2 N atoms; cycle B optionally contains 1-3 substituents R; R is independently selected and represents LR, LH, halogen, partially or fully halogenated C-alkyl; L is a covalent chemical bond, O, OCH, or C (O); R is independently selected and is C- alkyl, 4-6 membered heteroalicyclic containing 1-2 N atoms and 0-1 O atom; R optionally contains 1-3 substituents R; R is independently selected and represents halogen, CH, NHR, N (R) or 5-6 membered heteroalicyclic containing 0-1 N atom and 0-1 O atom; R optionally contains 1-2 substituents that are independently selected from C-alkyl; R is independently selected and is C-alkyl; to provide a pharmaceutical composition for treating and / or preventing a disease associated with aberrant activity of NUAK1 kinase. 2. The use according to claim 1, wherein: L is CH; L is C (O) NH; cycle A is phenyl optionally substituted with 1-3 R groups; R is independently selected and is halogen or CF; cycle B is phenyl; cycle B optionally contains 1-3 substituents R; R is independently selected and represents LR, LH; L is a covalent chemical bond, O, OCH or C (O); R is independently selected and is 4-6 membered heteroalicyclic containing 1-2 N atoms and 0-1
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015110071A RU2015110071A (en) | 2015-03-23 | 2015-03-23 | APPLICATION OF NEW CHEMICAL COMPOUNDS (OPTIONS) AS NUAK1 KINASE INHIBITORS FOR TREATMENT OF ONCOLOGICAL DISEASES |
PCT/RU2016/000157 WO2016153394A1 (en) | 2015-03-23 | 2016-03-22 | Use of novel chemical compounds (variants) as nuak1 kinase inhibitors for treating oncological diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015110071A RU2015110071A (en) | 2015-03-23 | 2015-03-23 | APPLICATION OF NEW CHEMICAL COMPOUNDS (OPTIONS) AS NUAK1 KINASE INHIBITORS FOR TREATMENT OF ONCOLOGICAL DISEASES |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015110071A true RU2015110071A (en) | 2016-10-10 |
Family
ID=56979130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015110071A RU2015110071A (en) | 2015-03-23 | 2015-03-23 | APPLICATION OF NEW CHEMICAL COMPOUNDS (OPTIONS) AS NUAK1 KINASE INHIBITORS FOR TREATMENT OF ONCOLOGICAL DISEASES |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2015110071A (en) |
WO (1) | WO2016153394A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2942001A (en) * | 1956-11-16 | 1960-06-21 | Ciba Pharm Prod Inc | Piperazo-pyridazines |
ES2610226T3 (en) * | 2010-10-08 | 2017-04-26 | Xcovery Holding Company Llc | 6-Amino-pyridazin-3-yl-carboxamide compounds substituted as protein kinase modulators |
RU2550346C2 (en) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | New chemical compounds (versions) and using them for treating oncological diseases |
-
2015
- 2015-03-23 RU RU2015110071A patent/RU2015110071A/en unknown
-
2016
- 2016-03-22 WO PCT/RU2016/000157 patent/WO2016153394A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2016153394A1 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2898765T3 (en) | Substituted quinazoline compounds and methods of use thereof | |
CA2876246C (en) | Substituted pyrazolone compounds and methods of use | |
JP2017533266A5 (en) | ||
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
RU2017145026A (en) | BRK INHIBITING COMPOUND | |
JP2017515802A5 (en) | ||
RU2005118417A (en) | COMBINED ADMINISTRATION OF INDOLINON WITH A CHEMOTHERAPEUTIC AGENT FOR DISORDERS CAUSED BY CELL PROLIFERATION | |
RU2014153627A (en) | IMIDAZO [1, 2-] Pyridazine derivatives as kinase inhibitors | |
JP2015523390A5 (en) | ||
RU2009125897A (en) | PHOSPHOINOSITIDE-3-KINASE INHIBITORS AND WAYS OF THEIR APPLICATION | |
WO2013180949A1 (en) | Substituted quinoline compounds and methods of use | |
JP2015536994A5 (en) | ||
RU2015116102A (en) | HETEROAROMATIC COMPOUNDS-MODULATORS OF PHOSPHOINOSIDIT-3-KINASES AND METHODS OF APPLICATION | |
EP3966213A1 (en) | Cdk inhibitors | |
JP2017513893A5 (en) | ||
CN104513258B (en) | Substituted urea derivative and its application in medicine | |
JP7293108B2 (en) | Combination therapy with Axl inhibitor and EGFR tyrosine kinase inhibitor | |
WO2022169998A1 (en) | Amides as cbl-b inhibitors | |
WO2020068600A1 (en) | Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof | |
RU2014142633A (en) | 6- (4- (1-amino-3-hydroxycyclobutyl) phenyl) -5-phenyl (furo, thieno or pyrrolo) [2,3-D] pyrimidine-4-new derivatives for the treatment of cancer | |
JP2020504139A5 (en) | ||
KR20220028075A (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | |
RU2008127264A (en) | Pyrimidylamino-benzamide derivatives for the treatment of neuro-fibromatosis | |
RU2015110071A (en) | APPLICATION OF NEW CHEMICAL COMPOUNDS (OPTIONS) AS NUAK1 KINASE INHIBITORS FOR TREATMENT OF ONCOLOGICAL DISEASES | |
UA87895C2 (en) | Substituted 5-phenyl pyrimidines i in therapy |